Skip to main content

Table 2 IC50 of c-Met inhibitors applied prior to HGF stimulation in the CELsignia test for six primary breast cancer cells with hyperactive both ErbB- and c-Met signaling

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

c-Met inhibitors

Average IC50 (nM)

Capmatinib

3.10

Savolitinib

3.56

Tepotinib

14.70

Cabozantinib

27.36

Crizotinib

28.21

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X